BEAM THERAPEUTICS INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$114M
↑+279.5% +$84Mvs FY2024 (Q4)
Gross Profit
$114M
↑+279.5% +$84Mvs FY2024 (Q4)
Operating Income
$9M
Net Income
$9M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $114M | $30M |
| COGS | $0 | $0 |
| Gross Profit | $114M | $30M |
| R&D | $99M | $101M |
| SG&A | $0 | $0 |
| D&A | $6M | $5M |
| Other OpEx | $0 | $0 |
| Operating Income | $9M | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $9M | $0 |
| Tax | $0 | $0 |
| Net Income | $9M | $0 |
QuarterCharts · SEC EDGAR data · BEAM · Comparing FY2025 (Q4) vs FY2024 (Q4)